RENB
RENB
Lunai Bioworks Inc. • NASDAQ
$1.42 ▲ 0.00% (+0.00)
Market Cap $32.92 M
52w High $21.00
52w Low $1.12
Dividend Yield 0%
P/E -0.13148148148148148
Volume 808.78K
Outstanding Shares 23.18M
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2024 | $0 | $4.162M ▼ | $189.176K ▲ | 0% | $0.012 ▲ | $409.836K ▲ |
| Q2-2024 | $0 | $4.546M ▼ | $-7.252M ▲ | 0% | $-0.448 ▲ | $-7.121M ▲ |
| Q1-2024 | $0 ▼ | $53.339M ▲ | $-44.212M ▼ | 0% ▲ | $-2.8 ▼ | $-43.93M ▲ |
| Q4-2023 | $181.454K ▲ | $51.294M ▲ | $-15.732M ▲ | -8.67K% ▼ | $-1.6 | $-52.191M ▼ |
| Q3-2023 | $0 | $8.77M | $-17.024M | 0% | $-1.6 | $-50.88M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2024 | $1.633M ▲ | $117.726M ▲ | $29.339M ▲ | $88.387M ▲ |
| Q2-2024 | $311.764K ▲ | $111.34M ▼ | $29.281M ▲ | $82.059M ▼ |
| Q1-2024 | $220.571K ▲ | $121.833M ▼ | $23.746M ▼ | $98.087M ▼ |
| Q4-2023 | $220.467K ▼ | $163.129M ▼ | $31.152M ▼ | $131.977M ▼ |
| Q3-2023 | $312.697K | $212.279M | $43.684M | $168.596M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2024 | $39.684T ▲ | $-1.487M ▲ | $-1.464M ▼ | $3.584M ▲ | $611.238K ▲ | $11.804T ▲ |
| Q2-2024 | $-7.252M ▲ | $-2.56M ▼ | $0 | $2.591M ▲ | $91.193K ▲ | $-2.56M ▼ |
| Q1-2024 | $-44.212M ▲ | $-2.016M ▲ | $0 ▲ | $2.029M ▼ | $104 ▲ | $-2.016M ▲ |
| Q4-2023 | $-49.922M ▼ | $-2.414M ▲ | $-53.373K ▲ | $2.467M ▼ | $-92.23K ▼ | $-2.437M ▲ |
| Q3-2023 | $-17.024M | $-2.634M | $-91.597K | $2.641M | $68.717K | $-2.639M |
Market Cap $32.92 M
52w High $21.00
52w Low $1.12
Dividend Yield 0%
P/E -0.13148148148148148
Volume 808.78K
Outstanding Shares 23.18M
About Lunai Bioworks Inc.
https://renovarogroup.comLunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2024 | $0 | $4.162M ▼ | $189.176K ▲ | 0% | $0.012 ▲ | $409.836K ▲ |
| Q2-2024 | $0 | $4.546M ▼ | $-7.252M ▲ | 0% | $-0.448 ▲ | $-7.121M ▲ |
| Q1-2024 | $0 ▼ | $53.339M ▲ | $-44.212M ▼ | 0% ▲ | $-2.8 ▼ | $-43.93M ▲ |
| Q4-2023 | $181.454K ▲ | $51.294M ▲ | $-15.732M ▲ | -8.67K% ▼ | $-1.6 | $-52.191M ▼ |
| Q3-2023 | $0 | $8.77M | $-17.024M | 0% | $-1.6 | $-50.88M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2024 | $1.633M ▲ | $117.726M ▲ | $29.339M ▲ | $88.387M ▲ |
| Q2-2024 | $311.764K ▲ | $111.34M ▼ | $29.281M ▲ | $82.059M ▼ |
| Q1-2024 | $220.571K ▲ | $121.833M ▼ | $23.746M ▼ | $98.087M ▼ |
| Q4-2023 | $220.467K ▼ | $163.129M ▼ | $31.152M ▼ | $131.977M ▼ |
| Q3-2023 | $312.697K | $212.279M | $43.684M | $168.596M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2024 | $39.684T ▲ | $-1.487M ▲ | $-1.464M ▼ | $3.584M ▲ | $611.238K ▲ | $11.804T ▲ |
| Q2-2024 | $-7.252M ▲ | $-2.56M ▼ | $0 | $2.591M ▲ | $91.193K ▲ | $-2.56M ▼ |
| Q1-2024 | $-44.212M ▲ | $-2.016M ▲ | $0 ▲ | $2.029M ▼ | $104 ▲ | $-2.016M ▲ |
| Q4-2023 | $-49.922M ▼ | $-2.414M ▲ | $-53.373K ▲ | $2.467M ▼ | $-92.23K ▼ | $-2.437M ▲ |
| Q3-2023 | $-17.024M | $-2.634M | $-91.597K | $2.641M | $68.717K | $-2.639M |
CEO
David H. Weinstein
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
CEO
David H. Weinstein
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 7, 2018
Method of going public SPAC
Full time employees 25
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-09-30 | Reverse | 1:10 |
Institutional Ownership
BLACKROCK INC.
3.657M Shares
$5.193M
NUVEEN ASSET MANAGEMENT, LLC
151.681K Shares
$215.387K
PARAMETRIC PORTFOLIO ASSOCIATES LLC
16.872K Shares
$23.958K
ALLWORTH FINANCIAL LP
122 Shares
$173.24
EVERSOURCE WEALTH ADVISORS, LLC
5 Shares
$7.1
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
0 Shares
$0
Summary
% Of Shares Owned 16.50%
Total Number Of Holders 6
Only Showing The Top 6